Stock ZTS ZOETIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zoetis Inc.

Equities

ZTS

US98978V1035

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 12:51:40 01/05/2024 am IST 		5-day change 1st Jan Change
159.5 USD -0.14% Intraday chart for Zoetis Inc. +6.82% -19.06%
01:30pm Stifel Adjusts Price Target on Zoetis to $180 From $195 MT
29/04 Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million DJ

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 63,038 78,657 1,15,457 68,303 90,615 72,974 - -
Enterprise Value (EV) 1 67,551 82,252 1,18,564 72,626 95,138 77,306 76,764 76,318
P/E ratio 42.6 x 48.4 x 57.1 x 32.6 x 38.9 x 29.2 x 26.4 x 24.4 x
Yield 0.52% 0.51% 0.44% 0.92% 0.79% 1.06% 1.21% 1.35%
Capitalization / Revenue 10.1 x 11.8 x 14.8 x 8.45 x 10.6 x 7.97 x 7.45 x 6.99 x
EV / Revenue 10.8 x 12.3 x 15.2 x 8.99 x 11.1 x 8.44 x 7.84 x 7.31 x
EV / EBITDA 24.6 x 28 x 34.5 x 20.4 x 25.6 x 19.3 x 17.6 x 16.5 x
EV / FCF 50.6 x 49.2 x 68.3 x 54.8 x 58.7 x 36.2 x 31.6 x 28.3 x
FCF Yield 1.98% 2.03% 1.46% 1.83% 1.7% 2.77% 3.17% 3.54%
Price to Book 23.2 x 20.9 x 25.4 x 15.4 x 18.1 x 12.2 x 10.4 x 8.57 x
Nbr of stocks (in thousands) 4,76,299 4,75,268 4,73,126 4,66,072 4,59,114 4,56,947 - -
Reference price 2 132.4 165.5 244.0 146.6 197.4 159.7 159.7 159.7
Announcement Date 13/02/20 16/02/21 15/02/22 14/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6,260 6,675 7,776 8,080 8,544 9,157 9,797 10,442
EBITDA 1 2,743 2,940 3,434 3,561 3,722 4,006 4,362 4,631
EBIT 1 2,331 2,499 2,986 3,096 3,231 3,535 3,857 4,178
Operating Margin 37.24% 37.44% 38.4% 38.32% 37.82% 38.6% 39.37% 40.01%
Earnings before Tax (EBT) 1 1,801 1,996 2,488 2,656 2,936 3,243 3,481 3,736
Net income 1 1,500 1,638 2,037 2,114 2,344 2,540 2,763 2,987
Net margin 23.96% 24.54% 26.2% 26.16% 27.43% 27.74% 28.2% 28.6%
EPS 2 3.110 3.420 4.270 4.490 5.070 5.475 6.038 6.556
Free Cash Flow 1 1,335 1,673 1,736 1,326 1,621 2,138 2,432 2,699
FCF margin 21.33% 25.06% 22.33% 16.41% 18.97% 23.35% 24.83% 25.85%
FCF Conversion (EBITDA) 48.67% 56.9% 50.55% 37.24% 43.55% 53.36% 55.76% 58.29%
FCF Conversion (Net income) 89% 102.14% 85.22% 62.72% 69.16% 84.15% 88.05% 90.38%
Dividend per Share 2 0.6920 0.8500 1.075 1.350 1.557 1.701 1.930 2.161
Announcement Date 13/02/20 16/02/21 15/02/22 14/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 1,990 1,967 1,986 2,052 2,002 2,040 2,000 2,180 2,151 2,213 2,148 2,324 2,309 2,364 2,274
EBITDA 1 839 756 946 887 879 849 857 - - - 898 977 970 962 -
EBIT 1 774 639 832 770 764 730 770 877 839 745 829.6 925.5 914.3 864.2 891
Operating Margin 38.89% 32.49% 41.89% 37.52% 38.16% 35.78% 38.5% 40.23% 39.01% 33.66% 38.61% 39.82% 39.6% 36.56% 39.18%
Earnings before Tax (EBT) 1 659 - - - - - - - - 650 768 849 846 840 -
Net income 1 552 414 595 529 529 461 552 671 596 525 583.4 686.5 657.2 633.7 -
Net margin 27.74% 21.05% 29.96% 25.78% 26.42% 22.6% 27.6% 30.78% 27.71% 23.72% 27.15% 29.53% 28.46% 26.81% -
EPS 2 1.160 0.8700 1.260 1.120 1.130 0.9900 1.190 1.450 1.290 1.140 1.267 1.448 1.416 1.342 1.330
Dividend per Share 2 0.2500 0.3250 0.3250 0.3250 0.3250 0.3250 0.3750 0.3750 - 0.8070 0.4150 0.4150 0.4150 0.4150 0.4600
Announcement Date 04/11/21 15/02/22 05/05/22 04/08/22 03/11/22 14/02/23 04/05/23 08/08/23 02/11/23 13/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 4,513 3,595 3,107 4,323 4,523 4,331 3,790 3,343
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 1.645 x 1.223 x 0.9048 x 1.214 x 1.215 x 1.081 x 0.8688 x 0.722 x
Free Cash Flow 1 1,335 1,673 1,736 1,326 1,621 2,138 2,432 2,699
ROE (net income / shareholders' equity) 71.7% 56.9% 49% 47.3% 52.3% 61.9% 45.8% 42.5%
ROA (Net income/ Total Assets) 15.7% 14.7% 14.8% 14.7% 16% 17% 17.1% 17.2%
Assets 1 9,539 11,172 13,754 14,413 14,606 14,949 16,133 17,333
Book Value Per Share 2 5.690 7.930 9.610 9.490 10.90 13.10 15.30 18.60
Cash Flow per Share 2 3.730 4.440 4.640 4.060 5.090 6.260 7.040 7.860
Capex 1 460 453 477 586 732 858 874 834
Capex / Sales 7.35% 6.79% 6.13% 7.25% 8.57% 9.37% 8.93% 7.99%
Announcement Date 13/02/20 16/02/21 15/02/22 14/02/23 13/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zoetis Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
159.7 USD
Average target price
213.9 USD
Spread / Average Target
+33.96%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
ZOETIS INC. Stock Zoetis Inc.
-19.06% 72.97B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-11.44% 6.69B
VIRBAC Stock Virbac
-3.48% 3.13B
VIMIAN GROUP AB Stock Vimian Group AB
+2.36% 1.44B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-15.13% 1.34B
VETOQUINOL SA Stock Vetoquinol SA
-7.91% 1.25B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-25.63% 1.24B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-10.84% 1.15B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
0.00% 1.01B
PULIKE BIOLOGICAL ENGINEERING, INC. Stock Pulike Biological Engineering, Inc.
-23.05% 817M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. ZTS Stock
  4. Financials Zoetis Inc.